Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for the heads-up Bothwell, sounds very promising indeed :-) Heimdal
Sorry what do you mean bothwell?
Lots of interested parities are trying to get information.
Heimdal
For once I agree with you……lol
My only reservation with what Bothwell posted, which, as you write, looks like an extract from an email received, is the time line. As mentioned before. If it took a whole year to just filter 30 participants, it’s going to take at least 2 years to get past the phase III goal posts. And since the company has never met a single announced deadline related to the US, I would take 18 months to be highly optimistic.
Hopefully multibagger is greater than 10 since I’m sure there are many that need at least 4 to 5x just to get back to even money given the dilution that has and is to occur.
Thanks Bothwell, sounds like a promising extract from a company e.mail. I like the bit part about "licensing partners have access to data room". As Bignose noted "Now that the marketing report is finished, there is now something with a lot more substance and of value to bring to the table and since this data will only have a finite timeline, a license agreement could well be in place long before the phase III finishes, although I am beginning to feel it may not now be as lucrative to us shareholders as we have been led to believe." I agree with Bignose and other posters that Fortacin will most likely not be a blockbuster, nonetheless, in light of the current ultra low MCap we should do fairly well once we secure a US license agreement. The combined income from China, EU, Taiwan, HK, Macao, USA and ROW will all add up and with a conservative P/E of 10-15 we must be looking at a multi-bagger from these shocking low levels. Heimdal
Can you elaborate bothwell as to why you think that after recent statements from bignose and Italians ? A counter point would be interesting
Just updating the current position in the USA. Looking very promising.
sorry bothell.not sure what you are referring to.is this something new?thanks
Market size analysis and price point sensitivity re-done by top tier US marketing organisation, licensing partners have access to data room and have been updated.
My guess is 12-18 months we will be in a better place.
The.Italian.
Correct. A true reflection of the companies investment abilities. The DBC and white elephants both come to mind.
problem is no sales and no revenue.you can ride the train out of the station fuelled on hope and expectation,but eventually you come to the red light and signal which says no further without sales or revenue.apologies for the silly analogy,but you get my meaning.i do not see how any serious investor( mellon's mates don't count) will ever get on board this particular train without evidence that we can sell the product.if it hasn't been on sale since feb/march then we won't be getting any numbers in next figures,so nothing to support any s/p improvement.hope I'm wrong.was mildly pleased to see zhavoronkov's puff piece (it actually did mention DLI and regent towards the end) as if he loses interest in DLI it will be another negative blow.obviously it will be years,if ever,before this aspect can become revenue positive I'm afraid.
Probably not until a US license is signed which needs to reflect the so called "blockbuster" product they have been presenting since the TO. Unfortunately, given the quality of the Chinese agreement, I'm now beginning to have my doubts.
this is now going to continue to drift down until something substantial is released, which is not expected for sometime yet. so the question is. How far will it go down ???
Do you honestly think any of this will make any difference given how the RPG's (or whatever) sp has performed in the last couple of years ? There is absolutely no confidence and nothing but contempt in the people running the company. Its so amusing that they write "in the companies lifetime over 260 mill usd has been returned to shareholders", yet, if one was an original RPG holder since 2013. They have seen their holding dilute by 65% following the TO and a further 30% since then with still no value returned, so its no wonder the market treats the company and its executives as a joke !!!
Very disappointing indeed. Sold down on low volume. Difficult to make any headway in this market.
Hang Seng Index back to JAN 1 level. VXR holding up well. ERPG MCAp just 37m pound now!
Sooner or later we must bounce from these crazy levels. A fair bit of news to look forward to for the rest
of this year: FDA Phase II submission AUG -> FDA green light, Start Phase III, Start clinical trials in China in OCT,
EU news, Taiwan, ?Japan, ?ROW, further developments on the DLI / longevity front, VXR exit? Given the news flow
coupled with the very low MCap we should hold up fairly well - limited downside. Heimdal
well that's friday's modest gains and some extra gone. very disappointing.